NCT07058064 WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
| NCT ID | NCT07058064 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-07-18 |
| Primary Completion | 2029-06-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2025-07-18 with a primary completion date of 2029-06-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and related morbidity and mortality. Mobile device-based artificial intelligence (AI)-electrocardiogram (ECG) can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors and smart watch based surveillance for cardiotoxicity is feasible and reliable.
Eligibility Criteria
Inclusion Criteria: * ability to understand study procedures and being willing to comply with them for the entire study length * diagnosis of lymphoma or sarcoma with new start or 1 year after completion of anthracycline therapy Exclusion Criteria: * LVEF \<50% at baseline, or prior confirmed history of heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm * Unwilling or unable to give written informed consent * Participants who have opted out of the Minnesota Research Authorization
Contact & Investigator
Joerg Herrmann, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT07058064 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07058064 currently recruiting?
Yes, NCT07058064 is actively recruiting participants. Contact the research team at Peck.Tera@mayo.edu for enrollment information.
Where is the NCT07058064 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT07058064 clinical trial?
NCT07058064 is sponsored by Mayo Clinic. The principal investigator is Joerg Herrmann, MD at Mayo Clinic. The trial plans to enroll 250 participants.